
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in China Biotech Services Holdings Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

- (1) PROPOSED GRANT OF GENERAL MANDATES
TO REPURCHASE SHARES AND TO ISSUE NEW SHARES;
(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
(3) PROPOSED RE-APPOINTMENT OF AUDITOR;
AND
(4) NOTICE OF ANNUAL GENERAL MEETING**

A notice convening the AGM to be held at 11:00 a.m. on Monday, 15 June 2026 at Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong is set out on pages AGM-1 to AGM-6 of this circular. A form of proxy for use by the Shareholders at the AGM is enclosed herein. Such form of proxy is also published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.cbshhk.com.

Whether or not you are able to attend the AGM, you are requested to complete and return the enclosed form of proxy in accordance with the instructions printed thereon and deposit the same to the branch share registrar and transfer office of the Company in Hong Kong, Union Registrars Limited at Suites 3301-04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong not less than 48 hours before the time appointed for holding the AGM or any adjourned AGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish. In such event, your form of proxy previously submitted will be deemed to be revoked.

This circular will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	<i>Page</i>
CHARACTERISTICS OF GEM	i
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I – EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE	I-1
APPENDIX II – BIOGRAPHICAL DETAILS OF RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED	II-1
NOTICE OF THE AGM	AGM-1

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“AGM”	the annual general meeting of the Company to be held at 11:00 a.m. on Monday, 15 June 2026 at Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong, the notice of which is set out on pages AGM-1 to AGM-6 of this circular, or any adjournment thereof
“Board”	the board of Directors
“Bye-laws”	the bye-laws of the Company as amended from time to time
“close associate(s)”	has the meaning ascribed thereto in the GEM Listing Rules
“Companies Act”	the Companies Act 1981 of Bermuda, as amended from time to time
“Company”	China Biotech Services Holdings Limited, a company incorporated in the Cayman Islands and continued in Bermuda with limited liability and the issued shares of which are listed on GEM (stock code: 8037)
“controlling shareholder(s)”	has the meaning ascribed thereto in the GEM Listing Rules
“core connected person(s)”	has the meaning ascribed to it under the GEM Listing Rules
“Director(s)”	the director(s) of the Company
“Extension Mandate”	a general and unconditional mandate proposed to be granted to the Directors to extend the General Mandate by the total number of Shares repurchased by the Company pursuant to and in accordance with the Repurchase Mandate
“GEM”	GEM operated by the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited as amended, supplemented or otherwise modified from time to time
“General Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise all powers of the Company to allot, issue or otherwise deal with Shares and/or (subject to compliance with the GEM Listing Rules, the Companies Act and any other applicable laws and regulations) to resell treasury shares of the Company up to an amount equal to 20% of the total number of issued Shares (excluding any treasury shares) as at the date of passing the resolution numbered 5 set out in the notice of the AGM

DEFINITIONS

“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	19 May 2026, being the latest practicable date prior to the publication of this circular for the purpose of ascertaining certain information contained herein
“Nomination Committee”	the nomination committee of the Company
“PRC”	the People’s Republic of China, and for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Repurchase Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise all powers of the Company to repurchase Shares which shall not exceed 10% of the number of the issued Shares (excluding any treasury shares) as at the date of passing the resolution numbered 4 set out in the notice of the AGM
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	ordinary share(s) of HK\$0.10 each in the share capital of the Company (or where there is any alteration to the nominal value of such share(s) after the passing of the relevant resolutions at the AGM, share(s) of such new nominal value in the share capital of the Company)
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed thereto in the GEM Listing Rules
“Takeovers Code”	the Code on Takeovers and Mergers issued by the Securities and Futures Commission in Hong Kong
“treasury shares”	has the meaning ascribed to it under the GEM Listing Rules
“%”	per cent

If there is any inconsistency in this circular between the Chinese and English versions, the English version shall prevail.

LETTER FROM THE BOARD



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

Executive Directors:

Mr. LIU Xiaolin (*Chairman*)
Dr. HUANG Song
Dr. YIN Ye

Registered office:

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Independent non-executive Directors:

Mr. YAN Guoxiang
Dr. GUO Yuantao
Dr. ZHANG Xiao

Head office and principal place of

business in Hong Kong:
Suites 1904-05A, 19/F, Sino Plaza
255-257 Gloucester Road
Causeway Bay, Hong Kong

22 May 2026

To the Shareholders

Dear Sir or Madam,

**(1) PROPOSED GRANT OF GENERAL MANDATES
TO REPURCHASE SHARES AND TO ISSUE NEW SHARES;
(2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; AND
(3) PROPOSED RE-APPOINTMENT OF AUDITOR**

1. INTRODUCTION

The purpose of this circular is to provide Shareholders with the notice of the AGM and information regarding (i) the grant of the Repurchase Mandate, the General Mandate and the Extension Mandate; (ii) the proposed re-election of the retiring Directors; and (iii) the proposed re-appointment of the auditor of the Company.

LETTER FROM THE BOARD

2. GENERAL MANDATES TO REPURCHASE AND ISSUE SHARES

The general mandates previously granted to the Directors to repurchase and issue Shares by the Shareholders at the last annual general meeting of the Company held on 5 June 2025 will expire at the conclusion of the AGM. In order to give the Company the flexibility to repurchase and issue Shares if and when appropriate, the following ordinary resolutions will be proposed at the AGM to approve the grant of new general mandates to the Directors:

- (a) to repurchase Shares on the Stock Exchange of up to 10% of the total number of issued Shares (excluding any treasury shares) on the date of passing such resolution (i.e. up to 97,573,115 Shares assuming that the total number of Shares in issue remains the same at 975,731,150 Shares from the Latest Practicable Date up to the date of passing such resolution and the Company does not have any treasury shares);
- (b) to allot, issue or deal with Shares and/or (subject to compliance with the GEM Listing Rules, the Companies Act and any other applicable laws and regulations) resell treasury shares of the Company of up to 20% of the total number of the issued Shares (excluding any treasury shares) on the date of passing such resolution (i.e. up to 195,146,230 Shares assuming that the total number of issued Shares remains the same at 975,731,150 Shares from the Latest Practicable Date up to the date of passing such resolution and the Company does not have any treasury shares); and
- (c) to extend the General Mandate by the total number of Shares repurchased by the Company pursuant to and in accordance with the Repurchase Mandate.

Details of the Repurchase Mandate and the General Mandate are set out in the proposed ordinary resolutions numbered 4 and 5 respectively of the notice of the AGM as set out on pages AGM-1 to AGM-6 of this circular. Both the General Mandate and the Repurchase Mandate will expire upon the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Bye-laws, the Companies Act or any other applicable laws of Bermuda to be held; or
- (iii) the passing of an ordinary resolution by the Shareholders in general meeting revoking or varying the authority granted to the Directors.

In accordance with the requirements of the GEM Listing Rules, the Company is required to send to the Shareholders an explanatory statement containing all the information reasonably necessary to enable them to make an informed decision on whether to vote for or against the grant of the Repurchase Mandate at the AGM. The explanatory statement for such purpose is set out in Appendix I to this circular.

LETTER FROM THE BOARD

3. PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS

As at the Latest Practicable Date, the Board comprised three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

Pursuant to Bye-law 83(2) of the Bye-laws, any Director appointed by the Directors from time to time to fill a casual vacancy of the Board or as an addition to the existing Board shall hold office until the first annual general meeting of the Company after his/her appointment and shall then be eligible for re-election.

Accordingly, Dr. Yin Ye (“**Dr. Yin**”) and Dr. Zhang Xiao (“**Dr. Zhang**”), who were appointed by the Board as an executive Director and an independent non-executive Director respectively on 25 July 2025 shall retire from office and being eligible, will offer themselves for re-election at the AGM.

In accordance with Bye-law 84(1) of the Bye-laws, at each annual general meeting, one-third of the Directors for the time being (or, if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement by rotation at least once every three years. The Directors to retire by rotation shall include, among others, those who have been longest in office since their last re-election or appointment. Any Director appointed pursuant to Bye-law 83(2) of the Bye-laws shall not be taken into account in determining which particular Directors or the number of Directors who are to retire by rotation.

As such, Dr. Huang Song (“**Dr. Huang**”) and Dr. Guo Yuantao (“**Dr. Guo**”) shall retire from office by rotation and being eligible to offer themselves for re-election at the AGM.

Biographical details of each of Dr. Huang, Dr. Yin, Dr. Guo, and Dr. Zhang are set out in Appendix II to this circular.

Recommendation of the Nomination Committee

The Nomination Committee, having reviewed the Board’s composition, nominated to the Board and for the Board to recommend to the Shareholders at the AGM Dr. Huang and Dr. Yin for re-election as executive Directors, and Dr. Guo and Dr. Zhang for re-election as independent non-executive Directors. The nominations were made in accordance with the nomination policy of the Company and the diversity aspects (including without limitation, gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service), and took into account the merits of the candidates as set out in Appendix II to this circular including, among others, their industry knowledge and experience. The Nomination Committee is of the view that each Director proposed to be re-elected will provide valuable contributions and objective and balanced views to the Board in relation to the Company’s affairs and, having considered the depth and breadth of professional experience, skills and knowledge of each of them, is satisfied that each of them will add and continue to add diversity to the Board and contribute to the Board with their skills and experience.

LETTER FROM THE BOARD

In particular, each of Dr. Guo and Dr. Zhang has confirmed that, and the Nomination Committee and the Board has noted that each of Dr. Guo and Dr. Zhang does not have any relationship with any Directors, senior management of the Company, substantial or controlling Shareholders, nor in any relationships or circumstances which would interfere with the exercise of his independent judgement to be an independent non-executive Director. Each of Dr. Guo and Dr. Zhang has also confirmed his/her independence pursuant to Rule 5.09 of the GEM Listing Rules and there are no other factors that may affect his/her independence in relation to the proposed appointment. The Nomination Committee and the Board have assessed each of Dr. Guo's and Dr. Zhang's independence, and are of the view each of Dr. Guo and Dr. Zhang has satisfied all the criteria for independence set out in Rule 5.09 of the GEM Listing Rules. When considering the re-election of Dr. Huang, Dr. Yin, Dr. Guo, and Dr. Zhang, the Nomination Committee has considered their extensive experience, working profiles and other merits as set out in Appendix II to this circular. The Nomination Committee is satisfied that each of Dr. Huang, Dr. Yin, Dr. Guo, and Dr. Zhang has the required character, integrity and experience to continuously fulfil their roles as executive Director and independent non-executive Director (as the case may be) effectively and provide appropriate balance of skills, diversity and independence to the Board.

Accordingly, the Nomination Committee has nominated, and the Board has recommended, the above retiring Directors, namely Dr. Huang, Dr. Yin, Dr. Guo, and Dr. Zhang, to stand for re-election as Directors at the AGM.

4. RE-APPOINTMENT OF AUDITOR OF THE COMPANY

An ordinary resolution will be proposed at the AGM to re-appoint RSM Hong Kong as the auditor of the Company and to authorise the Board to fix the auditor's remuneration. The estimated audit fee as agreed with RSM Hong Kong for the financial year ending 31 December 2026 is expected to be in the range of HK\$1.2 million to HK\$1.4 million. The estimated audit fee was determined after arm's length negotiations between the Company and RSM Hong Kong with reference to, among other things, (i) the audit fee for the previous financial year; (ii) the scope of the audit and the expected level of audit services; (iii) the expected audit timetable; and (iv) the level of professional staff and resources required to complete the audit services. The estimated audit fee is based on the information currently available to the Company and RSM Hong Kong as at the Latest Practicable Date and may be subject to adjustment if there is any material change in the audit scope, the Group's business and operations, audit timetable or other relevant circumstances.

5. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the AGM is set out on pages AGM-1 to AGM-6 of this circular. At the AGM, resolutions will be proposed to approve, inter alia, (i) the grant of the Repurchase Mandate, the General Mandate and the Extension Mandate; (ii) the proposed re-election of Directors; and (iii) the proposed re-appointment of the auditor of the Company.

In compliance with the GEM Listing Rules and the Bye-laws, all resolutions will be voted on by way of a poll at the AGM.

LETTER FROM THE BOARD

A form of proxy for use at the AGM is enclosed with this circular. Such form of proxy is also published on the websites of The Stock Exchange at www.hkexnews.hk and the Company at www.cbshhk.com. Whether or not you are able to attend the AGM, you are requested to complete the accompanying form of proxy in accordance with the instructions printed thereon and return it to the branch share registrar and transfer office of the Company in Hong Kong, Union Registrars Limited at Suites 3301-04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong not less than 48 hours before the time appointed for holding the AGM or any adjourned AGM. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

As at the Latest Practicable Date, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, the Directors confirm that no Shareholder is required to abstain from voting at the AGM.

6. CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Wednesday, 10 June 2026 to Monday, 15 June 2026, both days inclusive. In order to determine the entitlement to attend and vote at the AGM, shareholders whose names appeared on the register of members of the Company at the close of business on Monday, 15 June 2026 will be entitled to attend and vote at the AGM. In order to qualify for attending and voting at the AGM, all transfers of Shares accompanied by the relevant share certificates and the appropriate transfer forms must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Union Registrars Limited at Suites 3301-04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong by 4:00 p.m. (Hong Kong time) on Tuesday, 9 June 2026.

7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

8. RECOMMENDATION

The Directors consider that the proposed resolutions as set out in the Notice of AGM, including, among other things, the proposed resolutions in relation to (i) the grant of the Repurchase Mandate, the General Mandate and the Extension Mandate; (ii) the proposed re-election of the retiring Directors; and (iii) the proposed re-appointment of the auditor of the Company are in the best interests of the Company, the Group and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favor of all the resolutions to be proposed at the AGM.

LETTER FROM THE BOARD

9. GENERAL INFORMATION

Your attention is drawn to the additional information set out in Appendix I (Explanatory Statement on the Repurchase Mandate) and Appendix II (Biographical Details of Retiring Directors Proposed to be re-elected) to this circular.

Yours faithfully,
On behalf of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

The following is an explanatory statement required by the GEM Listing Rules to be sent to the Shareholders to enable them to make an informed decision on whether to vote for or against the ordinary resolution to be proposed at the AGM in relation to the grant of the Repurchase Mandate.

1. REASONS FOR REPURCHASE OF SHARES

The Directors believe that the grant of the Repurchase Mandate is in the interests of the Company and the Shareholders as a whole.

When exercising the Repurchase Mandate, the Directors may, subject to market conditions and the Company's capital management needs at the relevant time of the repurchases, resolve to cancel the Shares repurchased following settlement of any such repurchase or (if permitted by the Bye-laws and all applicable laws of Bermuda) hold them as treasury shares. Shares repurchased for cancellation may, depending on the market conditions and funding arrangements at the time, result in an enhancement of the net asset value per Share and/or earnings per Share. On the other hand, Shares repurchased and held by the Company as treasury shares may be resold on the market at market prices to raise funds for the Company, or transferred or used for other purposes, subject to compliance with the GEM Listing Rules, the Bye-laws, the Companies Act and the laws of the Bermuda, Share repurchases will only be made when the Directors believe that such repurchase will benefit the Company and the Shareholders as a whole.

To the extent that any treasury Shares would be deposited with the Central Clearing and Settlement System ("CCASS") pending resale on the Stock Exchange, the Company would adopt appropriate measures to ensure that it would not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in the Company's own name as treasury Shares. Such measures may include, for example, an approval by the Board that (i) the Company would not (or would procure its broker not to) give any instructions to Hong Kong Securities Clearing Company Limited to vote at general meetings for the treasury Shares deposited with CCASS and (ii) in the case of dividends or distributions, the Company would withdraw the treasury Shares from CCASS, and either re-register them in its own name as treasury Shares or cancel them, in each case before the record date for the dividends or distributions.

2. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 975,731,150 Shares and the Company did not have any treasury shares.

Subject to the passing of the ordinary resolution set out in resolution numbered 4 of the notice of the AGM in respect of the grant of the Repurchase Mandate and assuming that the total number of issued Shares (excluding any treasury shares) remains the same at 975,731,150 Shares from the Latest Practicable Date up to the date of passing such resolution, the Directors would be authorised under the Repurchase Mandate to repurchase, during the period in which the Repurchase Mandate remains in force, up to 97,573,115 Shares, representing 10% of the total issued Shares (excluding any treasury shares) as at the date of the AGM.

3. FUNDING OF REPURCHASES

In repurchasing Shares, the Company may only apply funds legally available for such purpose in accordance with its memorandum of continuance and the Bye-laws, the Companies Act, the laws of Bermuda and/or any other applicable laws, as the case may be.

4. IMPACT OF REPURCHASES

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in its latest audited accounts contained in the annual report of the Company for the year ended 31 December 2025) in the event that the Repurchase Mandate is to be carried out in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as it would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

5. TAKEOVERS CODE

If, as a result of a repurchase of Shares, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purpose of the Takeovers Code.

As a result, a Shareholder, or a group of Shareholders acting in concert (within the meaning of the Takeovers Code), depending on the level of increase in the Shareholders' interests, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, Mr. Liu Xiaolin is (i) interested in 4,692,000 Shares as legal and beneficial owner, and (ii) deemed to be interested in 529,500,546 Shares, held by Genius Lead Limited, which is wholly-owned by Genius Earn Limited, and is in turn wholly-owned by Mr. Liu Xiaolin. The 534,192,546 Shares in which Mr. Liu Xiaolin is or is deemed to be interested represent approximately 54.75% of the issued Shares as at the Latest Practicable Date. In the event that the Directors exercise the Repurchase Mandate in full and assuming there is no other change in the issued share capital of the Company nor the number of Shares in which Mr. Liu Xiaolin is interested or deemed to be interested, Mr. Liu Xiaolin's interest in the Shares will be increased to approximately 60.83% of the issued Shares. Such increase would not give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, the Directors had no intention to exercise the Repurchase Mandate to an extent which will trigger the mandatory offer requirement pursuant to the rules of the Takeovers Code or which will result in the amount of the Shares held by the public being reduced to less than the prescribed minimum percentage of 25%.

6. GENERAL

None of the Directors or, to the best of their knowledge after having made all reasonable enquiries, any of their respective close associates has any present intention to sell any Shares to the Company in the event that the grant of the Repurchase Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons of the Company that they have a present intention to sell any Shares to the Company or that they have undertaken not to sell any Shares held by them to the Company, in the event that the grant of the Repurchase Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to make repurchases of Shares pursuant to the Repurchase Mandate in accordance with the GEM Listing Rules and the applicable laws of Bermuda. Neither the Explanatory Statement nor the proposed share repurchase has any unusual features.

7. MARKET PRICES OF SHARES

The highest and lowest prices per Share at which the Shares were traded on the Stock Exchange in the last 12 months were as follows:

Month	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2025		
May	0.85	0.38
June	0.92	0.60
July	0.82	0.59
August	1.33	0.60
September	1.21	0.93
October	1.05	0.75
November	1.04	0.75
December	0.99	0.75
2026		
January	0.92	0.67
February	0.88	0.72
March	0.87	0.65
April	0.83	0.65
May (up to the Latest Practicable Date)	0.72	0.58

8. REPURCHASE OF SHARES MADE BY THE COMPANY

No repurchase of Shares (whether on the Stock Exchange or otherwise) has been made by the Company in the six months preceding the Latest Practicable Date.

Pursuant to the GEM Listing Rules, the details of the Directors who will retire at the AGM according to the Bye-laws and will be proposed to be re-elected at the same meeting are provided below.

1. Dr. Huang Song (“Dr. Huang”), executive Director

Dr. Huang, aged 44, was appointed as a non-executive Director on 15 September 2017 and was redesignated as an executive Director on 16 December 2019.

Dr. Huang joined the National Institute of Biological Sciences, Beijing, the PRC, in February 2011 as a postdoctoral research fellow and currently serves as a deputy director of administration and a director of its Synthetic Biology Center (合成生物生物學中心), where he is mainly responsible for research management and institutional operation. Dr. Huang has published several research papers in top journals in relation to cancer and aging mechanism, and jointly owns a patent of potential prostate cancer treatment.

Dr. Huang obtained a Bachelor’s degree in biological science from Peking University in July 2003 and a Doctor of Philosophy (PhD) degree in integrative biology from Graduate School of Biomedical Sciences, the University of Texas Southwestern Medical Center at Dallas in December 2010.

Dr. Huang has entered into a renewed letter of appointment with the Company, pursuant to which he has been appointed as an executive Director for a term of one year commencing from 16 December 2025, unless terminated by one month’s prior written notice given by either party to the other and is subject to retirement by rotation and re-election at the annual general meetings of the Company and other related provisions as stipulated in the Bye-laws and the GEM Listing Rules. Dr. Huang is entitled to a director’s fee of HK\$50,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities, as well as the prevailing market conditions. He is also entitled to discretionary bonus, share options under share option scheme and share awards under share award scheme to be determined by the Board with reference to his performance and the performance of the Group.

As at the Latest Practicable Date, Dr. Huang did not have any interest in the Shares within the meaning of Part XV of the SFO. Save as disclosed, Dr. Huang (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) did not hold any other positions with the Company or other members of the Group; (iii) did not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; and (iv) had not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules, and there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules nor other matters relating to the re-election of Dr. Huang that need to be brought to the attention of the Shareholders.

2. Dr. Yin Ye (“Dr. Yin”), executive Director

Dr. Yin, aged 46, has been appointed as an executive Director on 25 July 2025.

Dr. Yin is the chief executive officer and executive director of the BGI Group, where he leads the teams to actively promote the industrial application of cutting-edge biotechnology and genomics research and works. He joined the BGI Group in 2002 and has served various positions within the group since then. He has served as a director and the vice president of BGI Genomics Co., Ltd. (a company listed on the Shenzhen Stock Exchange with stock code: 300676.SZ) (“**BGI Genomics**”) until June 2024, the general manager of BGI Genomics, the general manager of BGI Medicine Co., Ltd.* (深圳華大基因醫學有限公司), the chief operating officer of Shenzhen BGI Technology Limited* (深圳華大基因科技有限公司), etc.

Dr. Yin obtained a bachelor’s degree in bioengineering from Dalian University of Technology in 2002, a master’s degree in bioengineering from South China University of Technology in 2013, and a PhD degree in Biology from the University of Copenhagen in 2019. He has also been certified by the BGI Genomics advanced professional and technical qualification assessment committee as a genomics researcher.

Dr. Yin has entered into a letter of appointment with the Company, pursuant to which he has been appointed as an executive Director for a term of three years commencing from 25 July 2025 unless terminated by one month’s prior written notice given by either party to the other, and is subject to retirement by rotation and re-election at the annual general meetings of the Company and other related provisions as stipulated in the Bye-laws and the GEM Listing Rules.

Pursuant to the letter of appointment, Dr. Yin is entitled to a director’s fee of HK\$50,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions. He is also entitled to discretionary bonus, share options under share option scheme and share awards under share award scheme to be determined by the Board with reference to his performance and the performance of the Group.

As at the Latest Practicable Date, Dr. Yin did not have any interest in the Shares within the meaning of Part XV of the SFO. Save as disclosed, Dr. Yin (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) did not hold any other positions with the Company or other members of the Group; (iii) did not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; and (iv) had not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules, and there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules nor other matters relating to the re-election of Dr. Yin that need to be brought to the attention of the Shareholders.

* For identification purposes only

3. Dr. Guo Yuantao (“Dr. Guo”), independent non-executive Director

Dr. Guo, aged 52, has been appointed as an independent non-executive Director on 6 June 2024. She is also the member of the audit committee, remuneration committee and nomination committee of the Company.

Dr. Guo has over 20 years of equity research experience in various international investment banks with both sector exposure and macro exposure. Dr. Guo was the former Chief Strategist and Economist, Head of Equity Research and Managing Director of the China Merchants Securities (Hong Kong) from 2017 to 2023. Prior to joining China Merchants Securities (Hong Kong), Dr. Guo was the former Head of Asia Consumer/Internet/Media Equity, Research and Managing Director of Jefferies (Hong Kong) from 2011 to 2017. Dr. Guo also has extensive international exposure from working as an analyst in the equity research team of HSBC (Hong Kong), Goldman Sachs (Gaohua Beijing) and Goldman Sachs (Singapore). Dr. Guo was accredited as a permanent member of the China Independent Non-Executive Directors Association (中國獨立非執行董事協會) in December 2023. Since 29 August 2024, Dr. Guo has been appointed as an independent non-executive director of Tianneng Power International Limited (stock code: 0819.HK), a company listed on the Stock Exchange.

Dr. Guo obtained a Bachelor of Arts with a major in International Economics from the School of Economics of Nankai University in 1995, a Master of Arts from the School of Economics of Peking University in 1998, and a Master of Philosophy from the Center of Development Studies and Churchill College of the University of Cambridge in 1999. Dr. Guo obtained her PhD from the Judge Business School and Churchill College of the University of Cambridge.

Dr. Guo has entered into a renewal letter of appointment with the Company, pursuant to which Dr. Guo has been appointed as an independent non-executive Director for a term of one year commencing from 6 June 2025, unless terminated by one month’s prior written notice given by either party to the other and is subject to retirement by rotation and re-election at the annual general meetings of the Company and other related provisions as stipulated in the Bye-laws and the GEM Listing Rules. Dr. Guo is entitled to a director’s fee of HK\$20,000 per month, which is determined by the Board on the recommendation of the remuneration committee of the Company with reference to her duties and responsibilities, as well as the prevailing market conditions.

As at the Latest Practicable Date, Dr. Guo did not have any interest in the Shares within the meaning of Part XV of the SFO. Save as disclosed, Dr. Guo (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) did not hold any other positions with the Company or other members of the Group; (iii) did not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; and (iv) had not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules, and there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules nor other matters relating to the re-election of Dr. Guo that need to be brought to the attention of the Shareholders.

4. Dr. Zhang Xiao (“Dr. Zhang”), independent non-executive Director

Dr. Zhang, aged 64, has been appointed as an independent non-executive Director on 25 July 2025. He is also a member of the audit committee of the Company.

Dr. Zhang has over 30 years of management experience in senior management within the healthcare sector. He was the global senior vice president and president of Greater China of Varian Medical Systems before his retirement in 2024. He joined Varian Medical Systems in 2013 as the managing director of China, responsible for the business of radiotherapy, proton therapy and its X-ray imaging components in China. In 2014, he was appointed as the global vice president and president of Greater China of Varian, responsible for the business in Mainland China and Taiwan. Under his leadership, Varian’s business continued to grow and had taken a leading position in the Greater China market. Dr. Zhang was committed to expanding the accessibility of tumor radiotherapy in China and improving the five-year survival rate of Chinese cancer patients. He has driven a series of transformative and innovative initiatives for Varian in China, including the launch of Halcyon, a next-generation intelligent radiotherapy platform, the application of advanced technologies such as artificial intelligence to create a comprehensive radiotherapy cloud solution, etc. Prior to joining Varian, he had worked in different business groups of General Electric.

Dr. Zhang obtained a Master of Science and a Doctor of Philosophy from the University of Tennessee, Knoxville in 1989 and 1992 respectively.

Dr. Zhang has entered into a letter of appointment with the Company, pursuant to which he has been appointed as an independent non-executive Director for a term of one year commencing from 25 July 2025, unless terminated by one month’s prior written notice given by either party to the other and is subject to retirement by rotation and re-election at the annual general meetings of the Company and other related provisions as stipulated in the Bye-laws and the GEM Listing Rules. Pursuant to the letter of appointment, Dr. Zhang is entitled to a director’s fee of HK\$20,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions.

As at the Latest Practicable Date, Dr. Zhang did not have any interest in the Shares within the meaning of Part XV of the SFO. Save as disclosed, Dr. Zhang (i) did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, or any other major appointments and professional qualifications; (ii) did not hold any other positions with the Company or other members of the Group; (iii) did not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company; and (iv) had not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules, and there is no further information to be disclosed pursuant to the requirements of Rule 17.50(2) of the GEM Listing Rules nor other matters relating to the re-election of Dr. Zhang that need to be brought to the attention of the Shareholders.

NOTICE OF THE AGM



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the “**Meeting**”) of China Biotech Services Holdings Limited (the “**Company**”) will be held at 11:00 a.m. on Monday, 15 June 2026 at Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong, for the following purposes:

Unless otherwise defined, capitalised terms used herein shall have the same meanings as ascribed to them in the circular of the Company dated 22 May 2026.

1. To receive and approve the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors (the “**Directors**”, each a “**Director**”) and the auditors of the Company for the year ended 31 December 2025.
2. To pass the following resolutions, each as a separate resolution:
 - (a) To re-elect Dr. Huang Song as an executive Director;
 - (b) To re-elect Dr. Yin Ye as an executive Director;
 - (c) To re-elect Dr. Guo Yuantao as an independent non-executive Director;
 - (d) To re-elect Dr. Zhang Xiao as an independent non-executive Director; and
 - (e) To authorise the board of Directors (“**Board**”) to fix the Directors’ respective remuneration.
3. To re-appoint RSM Hong Kong, Certified Public Accountants, as the auditors of the Company and to authorise the Board to fix its remuneration.

NOTICE OF THE AGM

To consider as special business and, if thought fit, pass with or without amendments, the following resolutions as ordinary resolutions:

ORDINARY RESOLUTIONS

4. **“THAT:**
- (a) subject to paragraphs (b) and (c) below, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to (or agree to) repurchase its shares (the “**Shares**”, each, a “**Share**”) in the issued Share capital of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), or any other stock exchange on which the Shares may be listed and which is recognised by the Securities and Futures Commission and the Stock Exchange for this purpose, subject to and otherwise in accordance with the requirements of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) or of any other stock exchange (as applicable) as amended from time to time, and all applicable laws, be and is hereby generally and unconditionally approved;
 - (b) the aggregate number of Shares to be purchased or agreed to be purchased pursuant to the approval in paragraph (a) above shall not exceed 10 per cent of the total number of the issued Shares (excluding any treasury shares) at the date of passing of this resolution, and the said approval shall be limited accordingly;
 - (c) if, after the passing of this resolution, the Company conducts a share consolidation or subdivision, the maximum number of Shares that may be repurchased subject to the limit set out in paragraph (b) above as a percentage of the total number of issued Shares (excluding any treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and
 - (d) for the purpose of this resolution, “**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the bye-laws of the Company or any applicable laws; or
 - (iii) the date on which the approval in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.”

NOTICE OF THE AGM

5. **“THAT:**

- (a) subject to compliance with the prevailing requirements of GEM Listing Rules, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue or otherwise deal with additional Shares and to grant rights to subscribe for, or convert any security into Shares (including the issue of any securities convertible into Shares, or options, warrants or similar rights to subscribe for any Shares), and to make or grant offers, agreements and options which would or might require the exercise of such powers during or after the end of the Relevant Period, be and is hereby generally and unconditionally approved;
- (b) the aggregate number of Shares allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) otherwise than pursuant to:
 - (i) a Rights Issue (as defined below);
 - (ii) any scrip dividend scheme or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the bye-laws of the Company in force from time to time;
 - (iii) an issue of Shares pursuant to the exercise of any options or award which may be granted under any option or award scheme or similar arrangement for the time being adopted for the grant or issue of Shares or rights to acquire Shares; or
 - (iv) any issue of Shares upon the exercise of rights of subscription or conversion under the terms of any warrants, convertible bonds, debentures, notes or any securities of the Company which carry rights to subscribe for or are convertible into Shares;

shall not exceed 20 per cent of the total number of issued Shares (excluding any treasury shares) as at the date of passing of this resolution and the said approval shall be limited accordingly;

- (c) if, after the passing of this resolution, the Company conducts a share consolidation or subdivision, the maximum number of Shares that may be issued together with the treasury shares which may be resold (if permitted under the GEM Listing Rules) subject to the limit set out in paragraph (b) above as a percentage of the total number of issued Shares (excluding any treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and

NOTICE OF THE AGM

(d) for the purposes of this resolution:

“**Relevant Period**” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the bye-laws of the Company or any applicable laws; or
- (iii) the date on which the approval in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting.

“**Rights Issue**” means an offer of Shares, or offer on issue of warrants, options or other securities giving rights to subscribe for Shares, open for a period fixed by the Directors to holders of Shares on the register of members of the Company on a fixed record date in proportion to their then holdings of such Shares (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognized regulatory body or any stock exchange outside Hong Kong).

Any reference to an allotment, issue, grant or offer of, or dealing with, Shares shall include a sale or transfer of treasury shares in the capital of the Company (including to satisfy any obligation upon the conversion or exercise of any convertible securities, options, warrants or similar rights to subscribe for Shares) to the extent permitted by, and subject to the provisions of, the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited, the Companies Act and any other applicable laws and regulations from time to time in force.”

NOTICE OF THE AGM

6. “**THAT** conditional upon the passing of the resolutions numbered 4 and 5 above, the general mandate to the Directors referred to in the resolution numbered 5 in the Notice be and is hereby extended by the addition to the number of Shares which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with (including the treasury shares which may be resold to the extent permitted by, and subject to the provisions of, the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited, the Companies Act and any other applicable laws and regulations from time to time in force) by the Directors pursuant to or in accordance with such general mandate of an amount representing the total number of Shares repurchased by the Company pursuant to or in accordance with the authority granted under resolution numbered 4 above, provided that such amount shall not exceed 10 per cent of the aggregate number of issued shares (excluding any treasury shares) as at the date of passing of the resolutions.”

On behalf of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 22 May 2026

Registered office:
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

*Head office and principal place
of business in Hong Kong:*
Suites 1904-05A, 19/F, Sino Plaza
255-257 Gloucester Road
Causeway Bay, Hong Kong

As at the date of this notice, the Directors are as follows:

Executive Directors:
Mr. LIU Xiaolin (*Chairman*)
Dr. HUANG Song
Dr. YIN Ye

Independent non-executive Directors:
Mr. YAN Guoxiang
Dr. GUO Yuantao
Dr. ZHANG Xiao

NOTICE OF THE AGM

Notes:

1. A member of the Company who is entitled to attend and vote at the Meeting convened by the above notice is entitled to appoint one or more proxies to attend the Meeting and vote on his/her/its behalf. A member who is the holder of two or more shares may appoint more than one proxy to represent him/her/it and to attend and vote in his/her/its stead at the Meeting.
2. A proxy need not be a member of the Company but must attend the Meeting in person to represent the member of the Company. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his/her/its attorney duly authorised in writing, or if the appointor is a corporation, either under seal or under the hand of an officer, attorney or other person authorized to sign the same.
3. In order to be valid, a form of proxy and the power of attorney or other authority (if any) under which it is signed, or a certified copy of such power or authority, must be deposited with the branch share registrar and transfer office of the Company in Hong Kong, Union Registrars Limited at Suites 3301-04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong not less than 48 hours before the time appointed for holding the Meeting or any adjourned Meeting. The completion and return of the form of proxy will not preclude a member from attending and voting in person at the Meeting or any adjournment thereof if he/she/it so wishes. In that event, his/her/its form of proxy previously submitted will be deemed to be revoked.
4. In the case of joint holders of a share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she/it were solely entitled thereto; but if more than one of such joint holders are present at the Meeting, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.
5. In compliance with the GEM Listing Rules and the bye-laws of the Company (as amended from time to time), resolutions to be proposed at the Meeting convened by this notice will be voted on by way of a poll.
6. For determining the entitlement of the shareholders of the Company to attend and vote at the Meeting, the register of members of the Company will be closed from Wednesday, 10 June 2026 to Monday, 15 June 2026 (both days inclusive) during which period no transfer of Shares will be effected. Shareholders whose names appeared on the register of members of the Company at the close of business on Monday, 15 June 2026 will be entitled to attend and vote at the AGM. In order to be entitled to attend and vote at the Meeting, all transfers of shares, accompanied by the relevant share certificates and the appropriate transfer forms, must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Union Registrars Limited of Suites 3301-04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong, for registration no later than 4:00 p.m. on Tuesday, 9 June 2026.
7. If tropical cyclone warning signal number 8 or above, "extreme conditions" announced by the HKSAR Government or a black rainstorm warning signal is in effect any time and remains in force 3 hours before the time of the Meeting on the date of the Meeting, the Meeting will be postponed. The Company will publish an announcement on the website of the Company at www.cbshhk.com and the HKEXnews website of the Stock Exchange at www.hkexnews.hk to notify the shareholders of the Company of the date, time and place of the rescheduled meeting.
8. If shareholders have any particular access request or special needs for participating in the Meeting, he/she will have to leave his/her contact information, including name, telephone number and email address to the Company by email to info@chinabioservices.com or by calling the Company's hotline at (852) 3188 3333 during business hours from 9:30 a.m. to 5:30 p.m. from Monday to Friday, excluding Hong Kong public holidays.